A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

A pill from Eli Lilly helped patients improve their blood sugar and shed weight, results that could propel the ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...